 |
 |
| BARDA funding is to support the development of a point-of-care diagnostic assay that potentially tests for four respiratory viruses: SARS-CoV-2 (Covid-19), Influenza A, Influenza B, and Respiratory Syncytial Virus. The respiratory virus panel would be developed to run on Quidel’s Sofia 2 flagship instrument. |
| © 2024 SPIE Europe |
|
